212 related articles for article (PubMed ID: 20372803)
21. Livin enhances chemoresistance in head and neck squamous cell carcinoma.
Yoon TM; Kim SA; Lee DH; Lee JK; Park YL; Lee KH; Chung IJ; Joo YE; Lim SC
Oncol Rep; 2017 Jun; 37(6):3667-3673. PubMed ID: 28440463
[TBL] [Abstract][Full Text] [Related]
22. Excision repair cross complementation group 1 immunohistochemical expression predicts objective response and cancer-specific survival in patients treated by Cisplatin-based induction chemotherapy for locally advanced head and neck squamous cell carcinoma.
Handra-Luca A; Hernandez J; Mountzios G; Taranchon E; Lacau-St-Guily J; Soria JC; Fouret P
Clin Cancer Res; 2007 Jul; 13(13):3855-9. PubMed ID: 17606717
[TBL] [Abstract][Full Text] [Related]
23. Targeting the DNA Repair Endonuclease ERCC1-XPF with Green Tea Polyphenol Epigallocatechin-3-Gallate (EGCG) and Its Prodrug to Enhance Cisplatin Efficacy in Human Cancer Cells.
Heyza JR; Arora S; Zhang H; Conner KL; Lei W; Floyd AM; Deshmukh RR; Sarver J; Trabbic CJ; Erhardt P; Chan TH; Dou QP; Patrick SM
Nutrients; 2018 Nov; 10(11):. PubMed ID: 30400270
[TBL] [Abstract][Full Text] [Related]
24. Butyrate response factor 1 enhances cisplatin sensitivity in human head and neck squamous cell carcinoma cell lines.
Lee SK; Kim SB; Kim JS; Moon CH; Han MS; Lee BJ; Chung DK; Min YJ; Park JH; Choi DH; Cho HR; Park SK; Park JW
Int J Cancer; 2005 Oct; 117(1):32-40. PubMed ID: 15880358
[TBL] [Abstract][Full Text] [Related]
25. The prognostic and predictive value of excision repair cross-complementation group 1 (ERCC1) protein in 1288 patients with head and neck squamous cell carcinoma treated with platinum-based therapy: a meta-analysis.
Bišof V; Zajc Petranović M; Rakušić Z; Samardžić KR; Juretić A
Eur Arch Otorhinolaryngol; 2016 Sep; 273(9):2305-17. PubMed ID: 26179868
[TBL] [Abstract][Full Text] [Related]
26. Lupeol suppresses cisplatin-induced nuclear factor-kappaB activation in head and neck squamous cell carcinoma and inhibits local invasion and nodal metastasis in an orthotopic nude mouse model.
Lee TK; Poon RT; Wo JY; Ma S; Guan XY; Myers JN; Altevogt P; Yuen AP
Cancer Res; 2007 Sep; 67(18):8800-9. PubMed ID: 17875721
[TBL] [Abstract][Full Text] [Related]
27. Inhibitor of DNA binding 2 is a novel therapeutic target for stemness of head and neck squamous cell carcinoma.
Bae WJ; Koo BS; Lee SH; Kim JM; Rho YS; Lim JY; Moon JH; Cho JH; Lim YC
Br J Cancer; 2017 Dec; 117(12):1810-1818. PubMed ID: 29096401
[TBL] [Abstract][Full Text] [Related]
28. XPD c.934G>A polymorphism of nucleotide excision repair pathway in outcome of head and neck squamous cell carcinoma patients treated with cisplatin chemoradiation.
Lopes-Aguiar L; Costa EF; Nogueira GA; Lima TR; Visacri MB; Pincinato EC; Calonga L; Mariano FV; de Almeida Milani Altemani AM; Altemani JM; Coutinho-Camillo CM; Ribeiro Alves MA; Moriel P; Ramos CD; Chone CT; Lima CS
Oncotarget; 2017 Mar; 8(10):16190-16201. PubMed ID: 26918827
[TBL] [Abstract][Full Text] [Related]
29. ERCC1 expression and outcomes in head and neck cancer treated with concurrent cisplatin and radiation.
Hayes M; Lan C; Yan J; Xie Y; Gray T; Amirkhan RH; Dowell JE
Anticancer Res; 2011 Dec; 31(12):4135-9. PubMed ID: 22199271
[TBL] [Abstract][Full Text] [Related]
30. Predictive Role of ERCC1 Expression in Head and Neck Squamous Cell Carcinoma Patients Treated with Surgery and Adjuvant Cisplatin-Based Chemoradiation.
Ciaparrone M; Caspiani O; Bicciolo G; Signorelli D; Simonelli I; de Campora L; Mazzarella G; Mecozzi A; Pianelli C; Camaioni A; Catalano P; Pasqualetti P; Fabiano A; Radici M; Marmiroli L; Corsi DC
Oncology; 2015; 89(4):227-34. PubMed ID: 26066774
[TBL] [Abstract][Full Text] [Related]
31. Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells: role of ERCC1-XPF.
Ferry KV; Hamilton TC; Johnson SW
Biochem Pharmacol; 2000 Nov; 60(9):1305-13. PubMed ID: 11008124
[TBL] [Abstract][Full Text] [Related]
32. CD10 as a novel marker of therapeutic resistance and cancer stem cells in head and neck squamous cell carcinoma.
Fukusumi T; Ishii H; Konno M; Yasui T; Nakahara S; Takenaka Y; Yamamoto Y; Nishikawa S; Kano Y; Ogawa H; Hasegawa S; Hamabe A; Haraguchi N; Doki Y; Mori M; Inohara H
Br J Cancer; 2014 Jul; 111(3):506-14. PubMed ID: 24874475
[TBL] [Abstract][Full Text] [Related]
33. Higher expression of XPF is a critical factor in intrinsic chemotherapy resistance of human renal cell carcinoma.
Zhang Q; Shi J; Yuan F; Wang H; Fu W; Pan J; Huang Y; Yu J; Yang J; Chen Z
Int J Cancer; 2016 Dec; 139(12):2827-2837. PubMed ID: 27542841
[TBL] [Abstract][Full Text] [Related]
34. Comparison of cisplatin sensitivity and the 18F fluoro-2-deoxy 2 glucose uptake with proliferation parameters and gene expression in squamous cell carcinoma cell lines of the head and neck.
Henriksson E; Kjellén E; Baldetorp B; Bendahl PO; Borg A; Brun E; Mertens F; Ohlsson T; Rennstam K; Wennerberg J; Wahlberg P
J Exp Clin Cancer Res; 2009 Feb; 28(1):17. PubMed ID: 19216775
[TBL] [Abstract][Full Text] [Related]
35. Increased interleukin-6 expression is associated with poor prognosis and acquired cisplatin resistance in head and neck squamous cell carcinoma.
Gao J; Zhao S; Halstensen TS
Oncol Rep; 2016 Jun; 35(6):3265-74. PubMed ID: 27108527
[TBL] [Abstract][Full Text] [Related]
36. Novel C-Terminal Heat Shock Protein 90 Inhibitors (KU711 and Ku757) Are Effective in Targeting Head and Neck Squamous Cell Carcinoma Cancer Stem cells.
Subramanian C; Kovatch KJ; Sim MW; Wang G; Prince ME; Carey TE; Davis R; Blagg BSJ; Cohen MS
Neoplasia; 2017 Dec; 19(12):1003-1011. PubMed ID: 29121598
[TBL] [Abstract][Full Text] [Related]
37. ERCC1 protein expression is associated with differential survival in oropharyngeal head and neck squamous cell carcinoma.
Patel MR; Zhao N; Ang MK; Stadler ME; Fritchie K; Weissler MC; Zanation AM; Harris SL; Funkhouser WK; Olshan AF; Shores CG; Hayes DN
Otolaryngol Head Neck Surg; 2013 Oct; 149(4):587-95. PubMed ID: 23846458
[TBL] [Abstract][Full Text] [Related]
38. The DNA damage response network in the treatment of head and neck squamous cell carcinoma.
Psyrri A; Gkotzamanidou M; Papaxoinis G; Krikoni L; Economopoulou P; Kotsantis I; Anastasiou M; Souliotis VL
ESMO Open; 2021 Apr; 6(2):100075. PubMed ID: 33714009
[TBL] [Abstract][Full Text] [Related]
39. Role of β-catenin in cisplatin resistance, relapse and prognosis of head and neck squamous cell carcinoma.
Roy S; Kar M; Roy S; Saha A; Padhi S; Banerjee B
Cell Oncol (Dordr); 2018 Apr; 41(2):185-200. PubMed ID: 29243047
[TBL] [Abstract][Full Text] [Related]
40. Identification of small molecule inhibitors of ERCC1-XPF that inhibit DNA repair and potentiate cisplatin efficacy in cancer cells.
Arora S; Heyza J; Zhang H; Kalman-Maltese V; Tillison K; Floyd AM; Chalfin EM; Bepler G; Patrick SM
Oncotarget; 2016 Nov; 7(46):75104-75117. PubMed ID: 27650543
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]